Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up - What's Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s stock price gapped up prior to trading on Friday . The stock had previously closed at $11.24, but opened at $13.71. Tonix Pharmaceuticals shares last traded at $13.03, with a volume of 7,112,338 shares changing hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research report on Monday. They set a "sell" rating on the stock.

Tonix Pharmaceuticals Trading Down 3.6 %

The company has a market capitalization of $22.33 million, a P/E ratio of 0.00 and a beta of 2.07. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company's fifty day simple moving average is $29.63 and its 200-day simple moving average is $25.95.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($23.00) EPS for the quarter, topping the consensus estimate of ($203.00) by $180.00. The company had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. Commonwealth Equity Services LLC acquired a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 120,292 shares of the company's stock, valued at approximately $40,000. Commonwealth Equity Services LLC owned 6.43% of Tonix Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.